Inhibition of the Anti-apoptotic Protein MCL-1 Severely Suppresses Human Hematopoiesis
Overview
Authors
Affiliations
BH3-mimetics inhibiting anti-apoptotic BCL-2 proteins represent a novel and promising class of antitumor drugs. While the BCL-2 inhibitor venetoclax is already FDA-approved, BCL-XL and MCL-1 inhibitors are currently in early clinical trials. To predict side effects of therapeutic MCL-1 inhibition on the human hematopoietic system, we used RNAi and the small molecule inhibitor S63845 on cord blood-derived CD34+ cells. Both approaches resulted in almost complete depletion of human hematopoietic stem and progenitor cells. As a consequence, maturation into the different hematopoietic lineages was severely restricted and CD34+ cells expressing MCL-1 shRNA showed a very limited engraftment potential upon xenotransplantation. In contrast, mature blood cells survived normally in the absence of MCL-1. Combined inhibition of MCL-1 and BCL-XL resulted in synergistic effects with relevant loss of colony-forming HSPCs already at inhibitor concentrations of 0.1 μM each, indicating "synthetic lethality" of the two BH3-mimetics in the hematopoietic system.
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia.
Wu Y, Zehnle P, Rajak J, Koleci N, Andrieux G, Gallego-Villar L Leukemia. 2023; 38(1):136-148.
PMID: 37945692 PMC: 10776398. DOI: 10.1038/s41375-023-02079-5.
PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia.
Shah K, Nasimian A, Ahmed M, Al Ashiri L, Denison L, Sime W Blood Cancer J. 2023; 13(1):139.
PMID: 37679323 PMC: 10484999. DOI: 10.1038/s41408-023-00914-7.
Jayappa K, Tran B, Gordon V, Morris C, Saha S, Farrington C J Clin Invest. 2023; 133(13).
PMID: 37166997 PMC: 10313372. DOI: 10.1172/JCI155938.
Shah K, Al Ashiri L, Nasimian A, Ahmed M, Kazi J Int J Mol Sci. 2023; 24(5).
PMID: 36902436 PMC: 10003524. DOI: 10.3390/ijms24055004.
Brinkmann K, Ng A, de Graaf C, Strasser A Cell Death Differ. 2022; 29(6):1079-1093.
PMID: 35388168 PMC: 9177562. DOI: 10.1038/s41418-022-00987-0.